{"id":"dextromethorphan-hbr","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"}]},"_chembl":null,"_dailymed":{"setId":"24cedaec-06a6-8fde-e063-6394a90a3d7a","title":"ULTRA CONCENTRATED DAYTIME/ NIGHTTIME SEVERE SOFTGEL (ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE SOFTGEL) KIT [CVS PHARMACY, INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dextromethorphan acts primarily as a non-competitive NMDA receptor antagonist, which suppresses cough signals in the central nervous system. It also exhibits sigma-1 receptor agonist activity, which may contribute to neuroprotective and anti-inflammatory effects. When formulated by Galera Therapeutics (likely as GalEra or in combination formulations), it may be investigated for additional therapeutic benefits beyond cough suppression, potentially including oral mucositis prevention or other supportive care indications.","oneSentence":"Dextromethorphan HBr is a sigma-1 receptor agonist and NMDA receptor antagonist that reduces cough by suppressing the cough reflex center in the medulla.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:30:06.829Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cough suppression (OTC/marketed indication)"},{"name":"Oral mucositis (potential pipeline indication under Galera development)"}]},"trialDetails":[{"nctId":"NCT05278494","phase":"NA","title":"Dextromethorphan for Treatment of Postoperative Pain","status":"RECRUITING","sponsor":"Nathanael Heckmann","startDate":"2022-09-15","conditions":"Post-operative Pain","enrollment":160},{"nctId":"NCT05068791","phase":"EARLY_PHASE1","title":"Psilocybin-facilitated Treatment for Chronic Pain","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-11-01","conditions":"Fibromyalgia, Primary","enrollment":30},{"nctId":"NCT06566794","phase":"NA","title":"KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2024-08-22","conditions":"Drug Interaction","enrollment":12},{"nctId":"NCT07284472","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia","status":"RECRUITING","sponsor":"Exciva GmbH","startDate":"2026-02-02","conditions":"Agitation Associated With Alzheimer's Disease Dementia","enrollment":300},{"nctId":"NCT06772753","phase":"PHASE1","title":"Investigation of Psychedelic Effects in Psychoactive Substances","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-02-05","conditions":"Psychedelic Effects in Healthy Volunteers","enrollment":50},{"nctId":"NCT06716645","phase":"PHASE4","title":"A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin","status":"COMPLETED","sponsor":"HALEON","startDate":"2024-12-04","conditions":"Common Cold, Cough","enrollment":244},{"nctId":"NCT06736509","phase":"PHASE3","title":"An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study","status":"TERMINATED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2024-11-21","conditions":"Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor","enrollment":139},{"nctId":"NCT06930872","phase":"PHASE1","title":"Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates","status":"COMPLETED","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2025-06-06","conditions":"Drug Interaction","enrollment":29},{"nctId":"NCT07386730","phase":"PHASE1","title":"A Study of Psychedelics in Healthy Older Adults With Low Well-being","status":"NOT_YET_RECRUITING","sponsor":"Jennifer Mitchell","startDate":"2026-03","conditions":"Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)","enrollment":80},{"nctId":"NCT04634669","phase":"PHASE2","title":"Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)","status":"TERMINATED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2020-09-23","conditions":"Treatment Resistant Depression, Major Depressive Disorder","enrollment":181},{"nctId":"NCT05444556","phase":"PHASE1","title":"A Study of Imlunestrant (LY3484356) in Female Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-07-07","conditions":"Healthy","enrollment":113},{"nctId":"NCT04947553","phase":"PHASE3","title":"A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2021-06-17","conditions":"Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor","enrollment":456},{"nctId":"NCT01435798","phase":"PHASE2","title":"Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical Trial","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2003-04","conditions":"Central Neuropathic Pain, Allodynia, Spinal Cord Injury","enrollment":26},{"nctId":"NCT02218203","phase":"PHASE2","title":"Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2003-04","conditions":"Central Neuropathic Pain, Allodynia, Spinal Cord Injury","enrollment":26},{"nctId":"NCT05557409","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2022-09-06","conditions":"Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation","enrollment":408},{"nctId":"NCT07241065","phase":"PHASE1","title":"A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-28","conditions":"Healthy Participants","enrollment":35},{"nctId":"NCT02446132","phase":"PHASE3","title":"Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2015-11-13","conditions":"Agitation in Patients With Dementia of the Alzheimer's Type","enrollment":1197},{"nctId":"NCT06383338","phase":"PHASE1","title":"A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2025-07-22","conditions":"Hodgkin Lymphoma, Non Hodgkin Lymphoma","enrollment":10},{"nctId":"NCT04899687","phase":"PHASE2","title":"Study of Dextromethorphan in OCD and Related Disorders","status":"RECRUITING","sponsor":"Stanford University","startDate":"2022-01-20","conditions":"Obsessive-Compulsive Disorder, Illness Anxiety Disorder, Body Dysmorphic Disorders","enrollment":60},{"nctId":"NCT03358706","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-02","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":28},{"nctId":"NCT04923659","phase":"EARLY_PHASE1","title":"Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-05-25","conditions":"Low Intensity Focussed Ultrasound","enrollment":20},{"nctId":"NCT05976646","phase":"PHASE1, PHASE2","title":"Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2023-09-18","conditions":"Addiction, Opioid Use, Substance Use Disorders","enrollment":18},{"nctId":"NCT06957223","phase":"NA","title":"Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asad Ullah Jan","startDate":"2025-05-06","conditions":"Major Depressive Disorder (MDD)","enrollment":80},{"nctId":"NCT05944510","phase":"PHASE4","title":"Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2023-08-31","conditions":"Treatment Resistant Schizophrenia","enrollment":40},{"nctId":"NCT06958692","phase":"PHASE3","title":"A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder","status":"RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2025-04-11","conditions":"Major Depressive Disorder (MDD)","enrollment":388},{"nctId":"NCT03547024","phase":"PHASE1","title":"A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2018-06-08","conditions":"Healthy","enrollment":14},{"nctId":"NCT06731335","phase":"PHASE2","title":"Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN","status":"RECRUITING","sponsor":"Unity Health Toronto","startDate":"2025-03-05","conditions":"Chronic Neuropathic Pain, Pain Management","enrollment":30},{"nctId":"NCT06632990","phase":"PHASE1","title":"A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates","status":"ACTIVE_NOT_RECRUITING","sponsor":"Allyx Therapeutics","startDate":"2024-11-04","conditions":"Drug Drug Interaction (DDI)","enrollment":36},{"nctId":"NCT03076021","phase":"PHASE4","title":"Effects of Isotretinoin on CYP2D6 Activity","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-07-26","conditions":"CYP2D6 Polymorphism","enrollment":33},{"nctId":"NCT06223880","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2023-12-27","conditions":"Major Depressive Disorder","enrollment":350},{"nctId":"NCT06693960","phase":"EARLY_PHASE1","title":"Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach","status":"RECRUITING","sponsor":"Washington State University","startDate":"2024-09-26","conditions":"Interaction","enrollment":16},{"nctId":"NCT03864042","phase":"PHASE1","title":"Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-02","conditions":"Advanced Solid Tumors, Metastatic Melanoma","enrollment":56},{"nctId":"NCT04887194","phase":"PHASE1","title":"PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates","status":"COMPLETED","sponsor":"Mirati Therapeutics Inc.","startDate":"2021-04-08","conditions":"Advanced Solid Tumor","enrollment":40},{"nctId":"NCT06348290","phase":"PHASE1","title":"Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2024-04-01","conditions":"Solid Tumor, Adult","enrollment":72},{"nctId":"NCT05129761","phase":"","title":"Clinical Response of Syrup Hydryllin® in Pakistani Subjects With Cough in Routine Practice","status":"COMPLETED","sponsor":"The Searle Company Limited Pakistan","startDate":"2021-11-28","conditions":"Cough","enrollment":320},{"nctId":"NCT04834427","phase":"PHASE4","title":"Safety and Efficacy Evaluation of S (+) - Ketamine in Children","status":"ENROLLING_BY_INVITATION","sponsor":"Chinese PLA General Hospital","startDate":"2022-04-20","conditions":"S-ketamine, Esketamine, Acute Pain","enrollment":3000},{"nctId":"NCT03720366","phase":"PHASE1","title":"A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-10-04","conditions":"Leukemia, Myeloid, Acute","enrollment":40},{"nctId":"NCT03718884","phase":"PHASE1","title":"A Study of Mirikizumab in Participants With Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-10-23","conditions":"Psoriasis","enrollment":29},{"nctId":"NCT03854019","phase":"PHASE3","title":"Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2019-08-05","conditions":"Huntington Disease, Irritability","enrollment":20},{"nctId":"NCT05181527","phase":"PHASE4","title":"Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2022-02-10","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT04392011","phase":"EARLY_PHASE1","title":"Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product","status":"COMPLETED","sponsor":"Washington State University","startDate":"2019-10-09","conditions":"Interaction Drug Food","enrollment":15},{"nctId":"NCT04797715","phase":"PHASE3","title":"Assessing Clinical Outcomes in Alzheimer's Disease Agitation","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2020-12-31","conditions":"Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor","enrollment":178},{"nctId":"NCT05699993","phase":"PHASE1","title":"A Study of IBI351 in Healthy Subjects","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-03-10","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT04201197","phase":"PHASE1","title":"Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-11-10","conditions":"Drug-Interactions","enrollment":22},{"nctId":"NCT05947604","phase":"PHASE1","title":"DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2023-02-09","conditions":"Trypanosomiasis, African","enrollment":20},{"nctId":"NCT03948243","phase":"PHASE1","title":"Licorice Botanical Dietary Supplements - Metabolism and Safety in Women","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2019-04-01","conditions":"Food-drug Interaction","enrollment":19},{"nctId":"NCT05602675","phase":"PHASE1","title":"A Drug Interaction Study of LY3871801 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-11-02","conditions":"Healthy","enrollment":39},{"nctId":"NCT05043805","phase":"PHASE4","title":"Dextromethorphan Added on for Children With Chronic Irritability","status":"UNKNOWN","sponsor":"Tri-Service General Hospital","startDate":"2021-05-09","conditions":"Irritable Mood","enrollment":120},{"nctId":"NCT03883581","phase":"PHASE1, PHASE2","title":"Impact of Nuedexta on Bulbar Physiology and Function in ALS","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-07-25","conditions":"Amyotrophic Lateral Sclerosis","enrollment":28},{"nctId":"NCT02442765","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2015-07-23","conditions":"Agitation in Patients With Dementia of the Alzheimer's Type","enrollment":387},{"nctId":"NCT03471767","phase":"PHASE2","title":"AXS-05 Phase II Trial on Smoking Behavior","status":"COMPLETED","sponsor":"James Davis","startDate":"2018-03-25","conditions":"Smoking Cessation, Smoking, Cigarette, Nicotine Dependence","enrollment":58},{"nctId":"NCT05334108","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport","status":"COMPLETED","sponsor":"Emalex Biosciences Inc.","startDate":"2022-04-26","conditions":"Drug Interaction","enrollment":56},{"nctId":"NCT04226352","phase":"PHASE1","title":"Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-03-15","conditions":"MDD, Treatment Resistant Depression, Smoking Cessation","enrollment":5},{"nctId":"NCT05236530","phase":"PHASE1","title":"Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-09","conditions":"Malaria","enrollment":48},{"nctId":"NCT02688088","phase":"PHASE1","title":"A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03-08","conditions":"Neoplasm Metastasis","enrollment":48},{"nctId":"NCT04039022","phase":"PHASE3","title":"Open-Label Safety Study of AXS-05 in Subjects With Depression","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-07-08","conditions":"Major Depressive Disorder, Treatment Resistant Depression, Depression","enrollment":876},{"nctId":"NCT04019704","phase":"PHASE3","title":"A Trial of AXS-05 in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-06-20","conditions":"Depression, Major Depressive Disorder","enrollment":327},{"nctId":"NCT02271893","phase":"PHASE2","title":"Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management","status":"TERMINATED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2014-11-25","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":19},{"nctId":"NCT02442778","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2015-11-11","conditions":"Agitation in Participants With Dementia of the Alzheimer's Type","enrollment":522},{"nctId":"NCT03738917","phase":"PHASE4","title":"Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.","status":"COMPLETED","sponsor":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","startDate":"2019-02-01","conditions":"Acute Bronchitis","enrollment":668},{"nctId":"NCT03538054","phase":"PHASE2","title":"Dextromethorphan in Fibromyalgia","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-06-26","conditions":"Fibromyalgia","enrollment":27},{"nctId":"NCT04044001","phase":"PHASE1, PHASE2","title":"BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2019-11-15","conditions":"Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis","enrollment":77},{"nctId":"NCT04608396","phase":"PHASE2","title":"Mechanistic Evaluation of Response in TRD (MERIT)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2020-08-13","conditions":"Treatment Resistant Depression, Major Depressive Disorder","enrollment":44},{"nctId":"NCT01767129","phase":"PHASE2","title":"Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Avanir Pharmaceuticals","startDate":"2013-10-16","conditions":"Dyskinesia, Parkinson's Disease","enrollment":14},{"nctId":"NCT01787136","phase":"","title":"Dextromethorphan Added on for the Patients With ADHD","status":"NO_LONGER_AVAILABLE","sponsor":"Tri-Service General Hospital","startDate":"","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT02174822","phase":"PHASE1","title":"A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-01","conditions":"Drug-drug Interaction","enrollment":56},{"nctId":"NCT04188028","phase":"NA","title":"Endobiotics for Phenotyping of Human Cytochrome P450 Enzymes","status":"COMPLETED","sponsor":"Jules Desmeules","startDate":"2019-01-01","conditions":"Healthy","enrollment":40},{"nctId":"NCT01584440","phase":"PHASE2","title":"Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease","status":"COMPLETED","sponsor":"Avanir Pharmaceuticals","startDate":"2012-08-13","conditions":"Agitation, Alzheimer's Disease","enrollment":220},{"nctId":"NCT01324232","phase":"PHASE2","title":"Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis","status":"COMPLETED","sponsor":"Avanir Pharmaceuticals","startDate":"2011-09-08","conditions":"Central Neuropathic Pain, Multiple Sclerosis","enrollment":209},{"nctId":"NCT04643249","phase":"PHASE1","title":"Drug-drug Interaction Study of KL1333 in Healthy Subjects","status":"COMPLETED","sponsor":"Abliva AB","startDate":"2020-11-10","conditions":"Mitochondrial Disease","enrollment":14},{"nctId":"NCT03595579","phase":"PHASE2","title":"Assessing Symptomatic Clinical Episodes in Depression","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2018-05-30","conditions":"Major Depressive Disorder","enrollment":97},{"nctId":"NCT02293096","phase":"NA","title":"Pharmacogenetic Prediction of Metoprolol Effectiveness","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2014-09","conditions":"Hypertension","enrollment":462},{"nctId":"NCT04525235","phase":"PHASE1","title":"Phenotyping of High Dose Rifampicin","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-01-07","conditions":"Tuberculosis","enrollment":25},{"nctId":"NCT02775240","phase":"PHASE1","title":"Study of SHP620 (Maribavir) in Healthy Adults","status":"COMPLETED","sponsor":"Shire","startDate":"2016-07-21","conditions":"Cytomegalovirus (CMV)","enrollment":18},{"nctId":"NCT04764851","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates","status":"TERMINATED","sponsor":"Emalex Biosciences Inc.","startDate":"2021-02-18","conditions":"Drug-Interactions","enrollment":30},{"nctId":"NCT02651116","phase":"PHASE4","title":"Dextromethorphan Pediatric Acute Cough Study","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-02-25","conditions":"Cough","enrollment":131},{"nctId":"NCT04837170","phase":"PHASE4","title":"Safety and Efficacy Evaluation of S (+) - Ketamine in Adults","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-05-01","conditions":"Postoperative Pain, Adults, Anesthesia","enrollment":12000},{"nctId":"NCT03714919","phase":"PHASE2","title":"A Pilot Study: a Non-opioid Technique for Postoperative Adenoidectomy Pain Relief in Pediatric Patients","status":"COMPLETED","sponsor":"Arlyne Thung","startDate":"2019-08-02","conditions":"Adenoid Hypertrophy","enrollment":10},{"nctId":"NCT04687566","phase":"PHASE2, PHASE3","title":"Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-08-11","conditions":"Amphetamine Addiction, Pharmacotherapy","enrollment":120},{"nctId":"NCT00535951","phase":"PHASE1","title":"Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-11","conditions":"Carcinoma, Non-Small-Cell Lung, Mesothelioma","enrollment":18},{"nctId":"NCT03729128","phase":"PHASE1, PHASE2","title":"Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder","status":"COMPLETED","sponsor":"Tzu-Yun Wang","startDate":"2018-07-24","conditions":"Stimulants Use Disorder","enrollment":85},{"nctId":"NCT02760615","phase":"PHASE4","title":"Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2016-11-01","conditions":"Colitis, Ulcerative, Crohn Disease","enrollment":""},{"nctId":"NCT02534038","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition","status":"TERMINATED","sponsor":"Avanir Pharmaceuticals","startDate":"2015-12","conditions":"Disinhibition Syndrome","enrollment":1},{"nctId":"NCT02727491","phase":"PHASE4","title":"Does Pre and Postoperative Dextromethorphan Reduce Post-tonsillectomy Pain in Children?","status":"COMPLETED","sponsor":"Dr. Rachel Rooney","startDate":"2012-03","conditions":"Pain, Postoperative","enrollment":85},{"nctId":"NCT02477670","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia","status":"COMPLETED","sponsor":"Avanir Pharmaceuticals","startDate":"2015-09","conditions":"Schizophrenia","enrollment":145},{"nctId":"NCT04233437","phase":"PHASE1","title":"Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects","status":"COMPLETED","sponsor":"Moleac Pte Ltd.","startDate":"2020-02-10","conditions":"Stroke","enrollment":27},{"nctId":"NCT03480009","phase":"PHASE3","title":"Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion","status":"COMPLETED","sponsor":"Study Investigator-Sponsor","startDate":"2018-07-28","conditions":"Abortion in First Trimester","enrollment":156},{"nctId":"NCT01441102","phase":"PHASE1, PHASE2","title":"Dextromethorphan for Diabetic Macular Edema","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2011-08","conditions":"Diabetic Macular Edema","enrollment":7},{"nctId":"NCT00003687","phase":"PHASE3","title":"Treatment for Chronic Pain in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1998-06-11","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":87},{"nctId":"NCT03420469","phase":"EARLY_PHASE1","title":"Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers","status":"COMPLETED","sponsor":"Indiana University","startDate":"2018-06-05","conditions":"Adverse Effect of Drug Therapy Metabolism Medications (Diagnosis)","enrollment":28},{"nctId":"NCT01367535","phase":"PHASE1","title":"Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2006-03","conditions":"Healthy Adults","enrollment":54},{"nctId":"NCT01832350","phase":"PHASE4","title":"Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease","status":"TERMINATED","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2012-08-28","conditions":"Alzheimer's Disease, Pseudobulbar Affect (PBA)","enrollment":34},{"nctId":"NCT02515526","phase":"NA","title":"Effect of Acute Ethanol Consumption on The Activity of Major Cytochrome P450 Enzymes, NAT2 and P-glycoprotein","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2015-06","conditions":"AOD Effects and Consequences","enrollment":16},{"nctId":"NCT02291666","phase":"PHASE4","title":"Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2015-04","conditions":"Type 2 Diabetes","enrollment":73},{"nctId":"NCT03415243","phase":"PHASE1","title":"To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-01","conditions":"Common Cold","enrollment":28},{"nctId":"NCT03792971","phase":"PHASE1","title":"Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Galera Therapeutics, Inc.","startDate":"2019-02-10","conditions":"Healthy","enrollment":13},{"nctId":"NCT02033707","phase":"PHASE1","title":"Effects of Hallucinogens and Other Drugs on Mood and Performance","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-04","conditions":"Healthy","enrollment":20},{"nctId":"NCT02987920","phase":"PHASE4","title":"Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2017-01","conditions":"Pain, Postoperative","enrollment":23},{"nctId":"NCT03054220","phase":"NA","title":"Impact of Genetic Polymorphism on Drug-Drug Interactions Involving CYP2D6","status":"COMPLETED","sponsor":"Jules Desmeules","startDate":"2016-07","conditions":"Healthy","enrollment":34},{"nctId":"NCT03505853","phase":"PHASE1","title":"A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2018-04-26","conditions":"Acute Intermittent Porphyria (AIP), Acute Hepatic Porphyria (AHP), Porphyria, Acute Intermittent","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dextromethorphan HBr","genericName":"Dextromethorphan HBr","companyName":"Galera Therapeutics, Inc.","companyId":"galera-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dextromethorphan HBr is a sigma-1 receptor agonist and NMDA receptor antagonist that reduces cough by suppressing the cough reflex center in the medulla. Used for Cough suppression (OTC/marketed indication), Oral mucositis (potential pipeline indication under Galera development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}